Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities research analysts have also issued reports on the company. Piper Sandler set a $3.00 target price on Kalaris Therapeutics and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Citizens Jmp initiated coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Kalaris Therapeutics in a research note on Wednesday, October 8th. Raymond James Financial assumed coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. Finally, Citigroup initiated coverage on shares of Kalaris Therapeutics in a report on Monday. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Kalaris Therapeutics Stock Up 0.4%

NASDAQ:KLRS opened at $4.75 on Friday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $17.25. The stock’s fifty day moving average price is $5.00. The firm has a market cap of $88.83 million, a P/E ratio of -1.17 and a beta of 0.42.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Institutional Trading of Kalaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Belpointe Asset Management LLC acquired a new position in Kalaris Therapeutics during the third quarter valued at approximately $231,000. Fortis Capital Advisors LLC purchased a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at $231,000. Finally, XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter valued at $65,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.